---
title: "AstraZeneca pays up to $1.5bn to license Dizal Pharma’s lung cancer drug"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292650413.md"
description: "A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser."
datetime: "2026-07-14T14:14:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292650413.md)
  - [en](https://longbridge.com/en/news/292650413.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292650413.md)
generator: "portal-rs"
---

# AstraZeneca pays up to $1.5bn to license Dizal Pharma’s lung cancer drug

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

### Related Stocks

- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)
- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [688192.CN](https://longbridge.com/en/quote/688192.CN.md)

## Related News & Research

- [Goldman Sachs Sticks to Their Buy Rating for AstraZeneca (AZN)](https://longbridge.com/en/news/296444477.md)
- [04:03 ETDizal to Present Emerging Data on ZEGFROVY® in Non-Small Cell Lung Cancer at WCLC 2026](https://longbridge.com/en/news/296585269.md)
- [Key facts: AstraZeneca (AZN) talks stall; €2.55bn bond, $198 PT](https://longbridge.com/en/news/296872454.md)
- [REG - AstraZeneca PLC - Update on eVOLVE-Lung02 Phase III trial](https://longbridge.com/en/news/296062318.md)
- [BREAKINGVIEWS-AstraZeneca's blocked M&A signals tough CEO finale](https://longbridge.com/en/news/296766497.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**